US Stock MarketDetailed Quotes

TVTX Travere Therapeutic

Watchlist

7.100
-0.230-3.14%

Close Jun 18 16:00 ET

7.100
0.0000.00%

Post 16:18 ET

540.52MMarket Cap-3567P/E (TTM)

Travere Therapeutic Stock Forum

Jaguar8

May 10 04:57

$Travere Therapeutic(TVTX.US)$
NEWS
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
Travere Therapeutics to present data on FILSPARI at prestigious medical conferences, demonstrating the potential superiority of FILSPARI over existing treatments
Analyses show FILSPARI's ability to slow kidney function decline in patients with IgA nephropathy, offering a new approach to patient care
New 48-week findings from...

Trytosaveabit

Apr 24 17:27

Update

$Travere Therapeutic(TVTX.US)$ Travere Therapeutics Says Berger's Disease Treatment Granted EU Conditional Marketing Authorization
MT Newswires· 43 mins Travere Therapeutics (TVTX) and CSL Vifor said Wednesday the European Commission granted conditional marketing authorization for Filspari as a treatment for adults with primary Immunoglobulin A Nephropathy, or Berger's disease.
CSL Vifor expects to launch sales of the drug in Europe beginning in H2. The authorizati...

Meltyy

Apr 18 16:34

🎯 Ph 3 readouts in Q2 2024...

$Travere Therapeutic(TVTX.US)$ Phase 3
$CG Oncology(CGON.US)$ Phase 3
$United Therapeutics(UTHR.US)$ Phase 3
$United Therapeutics(UTHR.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3
$Insmed(INSM.US)$ Phase 3
$GlycoMimetics(GLYC.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$UroGen Pharma Ltd(URGN.US)$ Phase 3
$Lyra Therapeutics(LYRA.US)$ Phase 3
$Citius Pharmaceuticals(CTXR.US)$ Phase 3
$Jaguar Health(JAGX.US)$ Phas...

Moomoo AI

Mar 15 22:07

The continuous decline in share price and revenue indicates unresolved challenges within the company. The company's future growth is uncertain and there are 4 warning signs in the investment analysis of Travere Therapeutics.

Further Weakness as Travere Therapeutics (NASDAQ:TVTX) Drops 14% This Week, Taking Three-year Losses to 72%

Trytosaveabit

Feb 23 20:11

Update

$Travere Therapeutic(TVTX.US)$ Travere Therapeutics And CSL Vifor Announced That The European Medicines Agency's CHMP Has Recommended Approval Of Sparsentan For Primary IgA Nephropathy With A Urine Protein Excretion >1.0 G/Day; European Commission Decision Is Expected In Q2 2024

Moomoo AI

Jan 9 19:48

Travere Therapeutics' future revenue performance is expected to decline, contributing to its low P/S. Shareholders accept this as they anticipate no pleasant surprises in future revenue. A strong share price rise seems unlikely under these circumstances.

Little Excitement Around Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Revenues

Trytosaveabit

Dec 14, 2023 20:47

Update

$Travere Therapeutic(TVTX.US)$ Travere Therapeutics Has Opened Enrollment In HARMONY Phase 3 Trial Of Pegtibatinase For Classical Homocystinuria Compared To Placebo In Participants Who Are Receiving Standard Of Care

Trytosaveabit

Dec 6, 2023 00:27

$Travere Therapeutic(TVTX.US)$ Never ceases to amaze me! A ticker actually get approval and falls? The a ticker gets a approval to just start and it goes 35%+! hehehe

Trytosaveabit

Dec 6, 2023 00:25

$Travere Therapeutic(TVTX.US)$ very nice! didn’t think it would go this high today! very nice

Trytosaveabit

Dec 5, 2023 19:49

Update

$Travere Therapeutic(TVTX.US)$ Travere Therapeutics Says Pre-NDA Meeting With FDA for IgA Nephropathy Drug 'Successful'; Plans 20% Job Cut; Shares Jump Pre-Bell
MT Newswires· 2 mins ago

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall